Catalyst Dossier · compiled by CeliA 🧫

Shionogi (SGIOY)

Healthcare · market cap $14.8B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Shionogi (SGIOY) is a Japanese pharmaceutical company with ~4,955 employees and a market cap of approximately $14.8B. The company fields a broad pipeline spanning infectious disease, CNS, women's health, and metabolic conditions, with multiple Phase 3 and Phase 2 assets. A recent PDUFA approval (May 29, 2026) represents the most immediate commercial milestone, though the specific approved asset is not identified in the provided facts.

The catalyst path

2026-12-30 (est.)Phase 2 · S-337395imp 7/10
2026-12-31 (est.)Phase 2 · Sivopixantimp 7/10
2027-04-16 (est.)Phase 2 · S-531011imp 7/10

Pipeline

Asset	Phase	Indication
Duloxetine Hydrochloride	Phase 3	Depressive Disorder
Ospemifene 60Mg Oral Tablet	Phase 3	Atrophy
S-606001	Phase 2	Pompe Disease
S-555739 Dose 1	Phase 2	Seasonal Allergic Rhinitis
Ospemifene (Dose 1)	Phase 3	Atrophy
Ospemifene 30 mg	Phase 3	Atrophy
Oral Glycopyrrolate Liquid	Phase 3	Cerebral Palsy
Meropenem	Phase 3	Healthcare-associated Pneumonia (HCAP)
S-309309	Phase 2	Obesity
Ospemifene 60 mg	Phase 3	Atrophy
S-892216	Phase 2	COVID-19
S-777469 400 mg	Phase 2	Atopic Dermatitis
Cefiderocol	Phase 3	Urinary Tract Infections
Ospemifene	Phase 3	Vaginal Dryness
S-337395	Phase 2	Respiratory Syncytial Virus Infections
S-531011	Phase 2	Solid Tumors
Lusutrombopag	Phase 3	Chronic Liver Disease
Standard of Care	Phase 2	Gram-negative Bacterial Infections
S-217622	Phase 3	SARS-CoV-2 Infection
Baloxavir Marboxil	Phase 3	Influenza

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SGIOY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.